DRI Healthcare Trust to Host First Quarter Earnings Call and Webcast on May 7, 2024

TORONTO, April 16, 2024 /CNW/ – DRI Healthcare Trust (TSX: DHT.UN) (TSX: DHT.U) (the "Trust") announces that it will hold a conference call to discuss its first quarter 2024 financial results on Tuesday, May 7, 2024, at 8:00 a.m. ET. The Trust will report its financial results on Monday, May 6, 2024, after market close.

All interested parties may join the conference call by dialing 416-764-8659 or 1-888-664-6392 approximately 15 minutes prior to the call to secure a line. Participants will be put on hold until the conference call begins. A question-and-answer session will follow management’s prepared remarks, at which time the operator will provide instructions for qualified equity analysts to submit questions.

A live webcast of the conference call, including a slide presentation, will be available at https://app.webinar.net/R08zEQyEgVn. Please connect at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to join the webcast. The webcast will be archived on the Trust’s website following the call date.

About DRI Healthcare Trust

DRI Healthcare Trust is managed by DRI Capital Inc. ("DRI Healthcare"), the pioneer in global pharmaceutical royalty monetization with a 35-year history of accelerating innovation by providing capital to inventors, academic institutions and biopharma companies. Since its founding in 1989, DRI Capital has deployed more than US$3.0 billion, acquiring more than 70 royalties on 45-plus drugs, including Eylea, Keytruda, Orserdu, Spinraza, Stelara, Vonjo, Zejula and Zytiga. DRI Healthcare Trust’s units are listed and trade on the Toronto Stock Exchange in Canadian dollars under the symbol "DHT.UN" and in U.S. dollars under the symbol "DHT.U". To learn more, visit drihealthcare.com or follow us on LinkedIn.

SOURCE DRI Healthcare Trust

Recent Posts

2024 Third Quarter Earnings Call

DRI Healthcare Trust Reports Third Quarter 2024 Results

DRI Healthcare Trust Announces Acquisition of a Synthetic Royalty Interest in the Worldwide Sales of Sebetralstat for...